Nazanin Abolhassani1, Julien Castioni1, Pedro Marques-Vidal2, Peter Vollenweider1, Gérard Waeber1. 1. Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland. 2. Department of Medicine, Internal Medicine, Lausanne University Hospital, Office BH10-642, Rue du Bugnon 46, 1011, Lausanne, Switzerland. Pedro-Manuel.Marques-Vidal@chuv.ch.
Abstract
OBJECTIVES: This study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample. METHODS: Baseline (2003-2006) and follow-up (2009-2012) data are from 4679 participants aged between 35 and 75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined: never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at follow-up), maintaining, or quitting. RESULTS: Polypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs were the most prescribed medicines at baseline and follow-up. Gender, age, obesity, smoking, previously diagnosed hypertension, or diabetes or dyslipidemia were significantly and independently associated with initiating and maintaining polypharmacy. CONCLUSION: In a population-based sample, prevalence of polypharmacy doubled over a 5.6-year period. The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status, and previously diagnosed cardiovascular risk factors.
OBJECTIVES: This study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample. METHODS: Baseline (2003-2006) and follow-up (2009-2012) data are from 4679 participants aged between 35 and 75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined: never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at follow-up), maintaining, or quitting. RESULTS: Polypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs were the most prescribed medicines at baseline and follow-up. Gender, age, obesity, smoking, previously diagnosed hypertension, or diabetes or dyslipidemia were significantly and independently associated with initiating and maintaining polypharmacy. CONCLUSION: In a population-based sample, prevalence of polypharmacy doubled over a 5.6-year period. The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status, and previously diagnosed cardiovascular risk factors.
Entities:
Keywords:
Determinants; General population; Polypharmacy; Switzerland; Trends
Authors: N Husson; G Watfa; M-C Laurain; C Perret-Guillaume; J-Y Niemier; P Miget; A Benetos Journal: J Nutr Health Aging Date: 2014-01 Impact factor: 4.075
Authors: Rebecca L Drieling; Andrea Z LaCroix; Shirley A A Beresford; Denise M Boudreau; Charles Kooperberg; Susan R Heckbert Journal: Am J Epidemiol Date: 2016-07-07 Impact factor: 4.897
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood Journal: Eur Heart J Date: 2013-06-14 Impact factor: 29.983
Authors: Amaia Calderón-Larrañaga; Luis A Gimeno-Feliu; Francisca González-Rubio; Beatriz Poblador-Plou; María Lairla-San José; José M Abad-Díez; Antonio Poncel-Falcó; Alexandra Prados-Torres Journal: PLoS One Date: 2013-12-20 Impact factor: 3.240
Authors: Caroline de Godoi Rezende Costa Molino; Patricia O Chocano-Bedoya; Angélique Sadlon; Robert Theiler; John E Orav; Bruno Vellas; Rene Rizzoli; Reto W Kressig; John A Kanis; Sophie Guyonnet; Wei Lang; Andreas Egli; Heike A Bischoff-Ferrari Journal: BMJ Open Date: 2022-04-29 Impact factor: 3.006
Authors: Monika P Oktora; Petra Denig; Jens H J Bos; Catharina C M Schuiling-Veninga; Eelko Hak Journal: PLoS One Date: 2019-03-22 Impact factor: 3.240
Authors: Lucas Morin; Kristina Johnell; Marie-Laure Laroche; Johan Fastbom; Jonas W Wastesson Journal: Clin Epidemiol Date: 2018-03-12 Impact factor: 4.790
Authors: Insa M Schmidt; Silvia Hübner; Jennifer Nadal; Stephanie Titze; Matthias Schmid; Barbara Bärthlein; Georg Schlieper; Thomas Dienemann; Ulla T Schultheiss; Heike Meiselbach; Anna Köttgen; Jürgen Flöge; Martin Busch; Reinhold Kreutz; Jan T Kielstein; Kai-Uwe Eckardt Journal: Clin Kidney J Date: 2019-05-24